Skip to Content

Silverback Therapeutics, Inc.

Merger

  • Date:
  • 7/22/2022
  • Company Name:
  • Silverback Therapeutics, Inc.
  • Stock Symbol:
  • SBTX
  • Company Name - Buyer:
  • ARS Pharmaceuticals
  • Status:
  • Investigating
  • Merger Announcement Date:
  • 7/21/2022

Case Finder

Locate any case using the tools below.

NEW YORK, July 22, 2022 – Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of Silverback Therapeutics, Inc. (NASDAQ: SBTX) (“Silverback”) breached their fiduciary duties or violated the federal securities laws in connection with the company’s acquisition by ARS Pharmaceuticals, Inc. (“ARS”).

On July 21, 2022, Silverback announced that it had entered into an agreement to be acquired by ARS in an all-cash deal valued at $265M. Pursuant to the merger agreement, Silverback equity holders are expected to own approximately 37% of the combined company. The deal is scheduled to close in the fourth quarter of 2022.

Bragar Eagel & Squire is concerned that Silverback’s board of directors oversaw an unfair process and ultimately agreed to an inadequate merger agreement. Accordingly, the firm is investigating all relevant aspects of the deal and is committed to securing the best result possible for Silverback’s stockholders.
The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in Silverback Therapeutics. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: